Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
OrphoMed logo — Innovative solutions for visceral hypersensitivity and pancr...

OrphoMed

Innovative solutions for visceral hypersensitivity and pancreatitis through pioneering therapeutic dimer conjugates.

Founded 2015 Series A Total: $41.82M Biotechnology, Pharmaceutical

General Information

Company Name OrphoMed
Founded Year 2015
Founders / Decision Makers
Team member
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Social

Get notified when OrphoMed moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About OrphoMed

OrphoMed is a San Francisco Bay Area based biotechnology and pharmaceutical company established in 2015. The company focuses on developing innovative therapeutic dimer conjugates through its proprietary DIMERx™ platform technology, with the aim of addressing visceral hypersensitivity and pancreatitis in gastrointestinal disorder treatments. The leading candidate, ORP-101, is a promising peripherally acting sodium ion channel blocker and mu agonist/kappa antagonist dimer, poised for specific indications in chronic treatment of conditions associated with visceral and somatic hypersensitivity and hyperalgesia. OrphoMed also aims to develop effective non-opioid and opioid conjugates for treating acute and chronic nociceptive pain. Moreover, the company's DIMERx™ technology creates conjugates tailored for various clinical indications, with new molecular entities enjoying composition of matter intellectual property protection. OrphoMed's activities have attracted significant attention from investors, with the most recent Series A investment amounting to $39.00M and involving prominent stakeholders such as New Enterprise Associates, Pappas Capital, Takeda Pharma, Mario Family Funds, and Relativity Healthcare Partners on 24 May 2017. The company's dedication to pioneering therapeutic solutions in the biotechnology and pharmaceutical industries presents promising prospects for future growth and development.

Taxonomy: pharmaceutical company, therapeutic dimer conjugates, DIMMERx technology, visceral hypersensitivity, pancreatitis, gastrointestinal disorders, peripheral neuropathic pain, systemic nociceptive pain, ORP-101, opioid alternatives, non-opioid analgesic, molecular entities, intellectual property, San Francisco Bay Area, drug development

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 5
Investor Investor Investor Investor
•••• •••• 		24 May 2017
Debt Financing •••••• - 15 Jan 2016

FAQ About OrphoMed

Innovative solutions for visceral hypersensitivity and pancreatitis through pioneering therapeutic dimer conjugates.
OrphoMed was founded in 2015.
OrphoMed operates in the following industries: Biotechnology, Pharmaceutical.
OrphoMed has completed 2 funding rounds, raising a total of $41.82M. The latest funding stage is Series A.

We're actively collecting intelligence on OrphoMed.

Track OrphoMed to get notified

Don't just browse. Track.

Signal Tracker monitors OrphoMed and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes